Key result
The prevalence of cardiometabolic multimorbidity in U.S. adults increased significantly from 1999 to 2018, reaching 14.4% in 2017-2018 (AAPC 3.6; 95% CI 2.1-5.3).
Why the study?
Cardiometabolic multimorbidity is increasingly common, but its prevalence in the United States remained unknown.
What is the prevalence and trend of cardiometabolic multimorbidity in U.S. adults from 1999 to 2018?
Population
US adults across 10 NHANES two-year cycles from 1999 to 2018
Comparison
Prevalence trends over time and across gender, age, and race/ethnicity strata
Design
Serial cross-sectional survey study
Authors
Loading...
Updated U.S. prevalence data guide surveillance; leaves open causal drivers and targeted interventions.
Cross-Sectional
Yes
What is the prevalence and trend of cardiometabolic multimorbidity in U.S. adults from 1999 to 2018?
Effect estimate: AAPC 3.6 (95% CI 2.1 to 5.3)
The prevalence of cardiometabolic multimorbidity in U.S. adults has significantly increased from 1999 to 2018, reaching 14.4% in 2017-2018, highlighting a growing public health issue.
Cheng et al. (2022) conducted a cross-sectional in Cardiometabolic multimorbidity. Calendar year (1999-2018) was evaluated on Prevalence and trends of cardiometabolic multimorbidity (AAPC 3.6, 95% CI 2.1 to 5.3). The prevalence of cardiometabolic multimorbidity in U.S. adults increased significantly from 1999 to 2018, reaching 14.4% in 2017-2018 (AAPC 3.6; 95% CI 2.1-5.3).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: